Program Partner: Vetter Pharma International GmbH
Audiovisual Sponsor: Patheon
Beverage Break Sponsor: Patheon
How is the market for outsourcing of drug substances and drug products faring now and projected to be in the future? Is the level of outsourcing up or down overall, and what Is the outlook for key customer bases? How are contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) evolving their business models and strategies to deal with client expectations for innovation, technology, capacity, and access to geographic markets? This program provides answers to these questions and will examine:
Pharmaceutical Outsourcing: Market Overview In-depth analysis of the market for contract development and manufacturing for drug substances and drug products, including levels of outsourcing, capacity utilization, trends in capital expenditures impacting outsourcing, and strategies for supplier differentiation.
Jim Miller, President, PharmSource, A GlobalData Company
In China, For China: Technology, Capacity, and Market Access Emerging markets were once seen only as a source for low-cost production, and outsourcing strategies were developed to leverage that cost advantage. As emerging markets become increasingly valuable as pharmaceutical end markets for multinational companies, a new paradigm is developing. Gain first-hand knowledge of the key issues involved in doing business in China and the potential advantages of domestic production in the strategies of sponsor companies for external development and manufacturing.
Bin Wang, PhD, Director, Strategic Marketing, Boehringer Ingelheim Biopharmaceuticals GmbH
Partnership Strategies: Innovation in Business Models and Technology What are the key issues in make-versus-buy decisions? Is it capacity- or technology-led or is it a combination of both that drives more strategic and collaborative partnerships? In a co-presentation, learn of innovative approaches that pharmaceutical companies and CDMOs/CMOs are taking in continuous manufacturing for solid dosage products and key take-aways that can be applied in other outsourcing models and activities.
What is the optimal business model for providing specialized technology-based contract seervices? Gain the insight of one company involved in such a decision involving solid-state chemistry and advanced polymorph screening services.
Livius Cotarca, PhD, Chief Scientific Officer, Synchro Morph Solutions SA
Attendees should pre-register and pre-pay for DCAT Week programs and events before March 15, 2017 (5pm ET). Confirmations and receipts will be emailed to registrants when payment is received.
Member Badges: On or about Thursday, March 16, 2017, DCAT members will receive an email with an e-ticket attachment confirming all of their pre-registrations for DCAT Week. Attendees should print the e-ticket (or store it on their phone) and bring it with them to DCAT Week. The QR code on the ticket can be used to quickly print a member badge or to scan attendees into all of the programs and events they have pre-registered for throughout the week. A separate badge system will be used for non-member registrants.
Badge Pickup Locations during DCAT Week:
Walk-ins are welcome if space permits. All walk-ins must pay with a credit card or check. Walk-ins cannot be invoiced.
Speaker bios have been requested from presenters and will be posted here as they are received.
Jim Bonner, PhD is a Senior Principal Engineer at Shire, leading the transformation of the batch process for Vyvanse (lisdexamfetamine) to continuous manufacturing. He serves in the Drug Product Group, ensuring quality production of Shire’s small-molecule products, efficient technical transfers, and collaborative CMO efforts. Dr. Bonner was formerly Director of Technical Operations at Merck & Co., Inc., where he managed drug product and packaging external manufacturing from a technical perspective. He also consulted for five years with The One When, a problem-solving and technology-transfer company. Dr. Bonner holds a MS from MIT and BS/PhD degrees from Georgia Tech, all in chemical engineering.
Livius Cotarca, PhD, is Chief Scientific Oofficer for Synchro Morph Solutions SA, a Swiss start-up company developing innovative business models in pharmaceutical solid-state characterization outsourcing. In 2016, he founded his own consultancy company, LC Consulting, providing expertise in process research and development for active pharmaceutical ingredients, advanced intermediates, and consultancy services for Synchro Morph Solutions SA. Prior to that, he was the Global Research and Industrial Development Director for the Zambon Group in Italy for more than 15 years and was Senior Chemist, and Group Leader at Caffaro - SNIA Group, Italy (1992– 1999).
Dr. Cotarca is co-author of three books, more than 60 patents on pharma active ingredients and processes and more than 50 papers in the field of organic and physical organic chemistry. His studies in physical organic chemistry have been directed to the understanding of structure and reaction mechanisms of technologically important organic compounds. He has contributed to the large-scale syntheses of monomers, antioxidants, fire retardants, lubricants, and herbicides. Currently, his scientific and technical interest is devoted to API process chemistry and solid-state characterization by using Synchrotron radiation. Dr. Cotarca’s papers on the chemistry of carbonic acid derivatives [e.g. chlorinated carbonates (triphosgene), isocyanates, ureas and heterocycles] suggest cleaner, inherently safer and environmentally friendly alternative phosgene-free methods. Such methods are collected in a co-authored handbook titled, Phosgenation. A Handbook, published by Wiley-VCH.
Dr. Cotarca is a recipient of the Nicolae Teclu Award for Chemistry from the Romanian Academy and the Premio alla Ricerca from the Italian Chemical Society. He is a member of the American Chemical Society and other advanced scientific associations.
Dr. Cotarca received his M. Sc. in Industrial Chemistry (organic intermediates, polymers, dyes and drug technology) and a PhD in Organic Chemistry from Polytechnic Institute Timisoara, Romania. He holds also a M.Sc. degree in Chemical Engineering from Polytechnic of Milan (Italy). He was Associate Professor of Organic Chemistry at Polytechnic Institute Timisoara (1978 – 1990) and Visiting Professor at Technical University Munich and the University of Bielefeld, Germany (1991).
Eric Jayjock, PhD, is Director of Continuous Manufacturing at Patheon, where he is focused on developing highly-flexible, highly-capable continuous manufacturing frameworks to serve the diverse needs of the pharmaceutical industry. Prior to Patheon, he was at Janssen, a Johnson & Johnson Company, joining the team that he had collaborated with during his graduate studies, designing and coordinating the construction of the National Science Foundation’s Center for Structured Organic Particulate (C-SOPS) continuous direct compression line. Eric Jayjock performed his graduate studies at Rutgers University, where he was a part of the National Science Foundation’s Center for Structured Organic Particulate (C-SOPS) systems. One of his main areas of research was the development of scalable manufacturing processes for oral solids dosages.
Jim Miller is the founder and president of PharmSource Information Services, Inc. A preeminent expert in bio/pharmaceutical outsourcing, he established and presides over the industry’s principal resource for serious consumers of information on contract drug development and manufacturing, PharmSource STRATEGIC ADVANTAGE. He is editor and publisher of Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report.
Mr. Miller serves as an Editorial Advisory Board member for Advanstar Communication’s Pharmaceutical Technology and BioPharm magazines. He writes regular columns on outsourcing for Pharmaceutical Technology, Contract Services Europe and BioPharm magazines. He chairs the advisory committee of the Pharma & Biopharma Outsourcing Association (PBOA), and is a member of the board of directors of the American Type Culture Collection (ATCC), and serves on its Technical Committee.
Mr. Miller was formerly vice president of sales and marketing at Circa Pharmaceuticals, Inc., a solid dose manufacturer. Prior to that, he was president of St. Anthony Publishing, a provider of database information services for the health care industry. He also was a consultant in corporate strategy with the Boston Consulting Group. He holds an MBA degree from the Stanford University Graduate School of Business.
Bin Wang, PhD is Director of Strategic Marketing at Boehringer Ingelheim Biopharmaceuticals GmbH. He works under an international Expatriate assignment in the function of Global Marketing, Communication & Business Intelligence of Boehringer Ingelheim Biopharmaceuticals Contract Manufacturing Business Unit, where he is responsible for various marketing & business intelligence projects with a focus on China. Previously, Dr. Wang has worked in Shanghai, as part of the core leadership team, and made important contributions in establishing the Boehringer Ingelheim Biopharmaceuticals China organization and operational framework.
InterContinental Barclay (Grand Ballroom)
111 East 48th Street
New York, New York 10017
Map & Directions
To cancel your program registration and receive a refund, you must call the DCAT office by March 15, 2017 (5pm ET) at +1-800-640-3228.
Refunds with receptions may be subject to a processing fee due to hotel guarantees.
The DCAT organization regrets that no refunds can be given after March 15, 2017 (5pm ET).
Registration payments made by credit card will be refunded within two to three business days from the date of cancellation.
Registration payments made by check will be refunded within 20 days of the program date.
Education program topics for DCAT Week are selected and developed by members of DCAT's Education Committee and other volunteer task forces of the organization. Speakers are selected based on their expertise and/or experience related to these topics, their ability to impart important information and concepts, and their willingness to do so without promoting specific business interests. By advance meetings with speakers, reviewing materials and slide presentations, DCAT volunteers make every effort to ensure that each program is a relevant, value-added experience for our members.
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.